Middle East & Africa Blood Transfusion Diagnostics Market

The MEA blood transfusion diagnostics market is expected to grow from US$ 151.99 million in 2022 to US$ 199.02 million by 2028. It is estimated to grow at a CAGR of 4.6% from 2022 to 2028. 

Technological Developments in Blood Transfusion Diagnostics to Brings New Trends to Market 

Blood transfusion diagnostics are usually deployed during long-hour surgeries, such as kidney transplants, and in cases of emergencies. These surgeries are associated with the chances of excessive blood loss, which makes it difficult to make up for the blood loss with new blood, especially in the case of rare blood groups. Due to the ample demand, key players in the blood transfusion diagnostics market are offering advanced and fully automated blood transfusion diagnostics that reduce human interventions. For instance, in April 2019, BD launched its BD BACTEC quality control media to help identify contaminated platelet units during transfusions. Many companies employ strategic activities, such as acquisitions and partnerships, to capture better shares in the market. In December 2019, Getinge purchased Applikon Biotechnology, a leader in the development and supply of innovative bioreactor systems suitable for all scales, ranging from laboratory to industrial. In October 2019, Medtronic acquired AV Medical Technologies. Such advancements are likely to bring new trends in the blood transfusion diagnostics market in the coming years. 

Market Overview 

In 2021, South Africa held the largest share of the blood transfusion diagnostics market in the MEA. The country records the increasingly high incidence of various chronic diseases, such as diabetes, cancer, cardiovascular, and infectious diseases, requiring surgical procedures as a treatment. Also, healthcare facilities in South Africa are developing and adopting the latest technologies to offer better treatments. An article titled ""Improving Sepsis Care in Africa, 2021"" estimated that ~85% of sepsis cases occur in low and middle-income countries, with the highest burden in Africa. In addition, children (especially newborns), pregnant women, and elderly people are the most affected population. In Africa, ~17 million cases and 3.5 million deaths occurred in 2017 due to sepsis. Further, the increasing cases of sickle cell anemia (SCD) and thalassemia in South Africa are likely to complement the blood transfusion diagnostics market in South Africa. According to data published in Pan African Medical Journal, the World Health Organization (WHO) estimates ~50 million people with sickle cell trait globally, with the cases reaching 38 million in sub-Saharan Africa; Africa has 500,000 children with sickle cell disease, and 70% die before they turn 5 years of age, due to the lack of adequate care. SCD patients frequently require a blood transfusion, which can be associated with the increased demand for blood transfusion diagnostics in the country. 

MEA Blood Transfusion Diagnostics Market Revenue and Forecast to 2028 (US$ Million) 

Middle East & Africa Blood Transfusion Diagnostics Strategic Insights

Strategic insights for the Middle East & Africa Blood Transfusion Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East & Africa Blood Transfusion Diagnostics Report Scope

Middle East & Africa Blood Transfusion Diagnostics Regional Insights

The geographic scope of the Middle East & Africa Blood Transfusion Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

MEA Blood Transfusion Diagnostics Market Segmentation 

The MEA blood transfusion diagnostics market is segmented based on product, application, end user, and country. 

Based on product, the MEA blood transfusion diagnostics market is bifurcated into instruments & kits and reagents. The instruments & kits segment held the larger market share in 2022. Based on application, the MEA blood transfusion diagnostics market is bifurcated into blood grouping and disease screening. The disease screening segment held the larger market share in 2022. Based on end user, the MEA blood transfusion diagnostics market is segmented into hospitals, diagnostic laboratories, blood banks, and plasma fractionation companies. The blood banks segment dominated the market in 2022. Based on country, the MEA blood transfusion diagnostics market has been categorized into the UAE, Saudi Arabia, South Africa, and Rest of the MEA. Our regional analysis states that South Africa dominated the market in 2022. Abbott; BAG Diagnostics GmbH; Bio-Rad Laboratories, Inc.; DiaSorin S.p.A.; F. Hoffmann-La Roche Ltd; Grifols, S.A.; Immucor, Inc.; Ortho Clinical Diagnostics (QuidelOrtho Corporation); Quotient Limited; and Thermo Fisher Scientific Inc. are the leading companies operating in the MEA blood transfusion diagnostics market.